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Abstract
Background: Stem cell therapy provides great hope for patients with diabetes mellitus (DM). DM is a seriously
alarming metabolic disease characterized by hyperglycemia and β cell dysfunction. Efficient novel therapeutic
modalities to treat DM are indeed warranted. Stem cells (SC) derived from the umbilical cord specifically provide
several advantages and unique characteristics being a readily available non-invasive source, with an additional
credit for their banking potential. This meta-analysis study aims to provide a focused assessment for therapeutic
efficacy of umbilical cord (UC)-derived SC-transplantation, namely Wharton’s jelly mesenchymal stem cells (WJMSCs) and umbilical cord blood (UCB) for DM.
Methods: The clinical efficacy was evaluated based on glycemic control status (reflected on HbA1c%) and β cell
function (reflected on C-peptide levels), as well as the daily insulin requirement in diabetic patients after receiving
UC-derived SC-transplantation compared to baseline values. Moreover, we assessed these outcome measures in
patients who received such intervention compared to those who did not receive it in randomized/non-randomized
controlled clinical trials. We employed a random-effects model and standardized mean difference for this metaanalysis.
Results: Eleven eligible clinical studies were included; WJ-MSCs (6 studies; 172 patients including 71 controls) and
UCB (5 studies; 74 patients including 15 controls). WJ-MSCs significantly improved HbA1c% (pooled-estimate −
1.085; 95%CI (− 1.513, − 0.657); p < 0.001) and C-peptide levels (pooled-estimate 1.008; 95%CI (0.475, 1.541);
p < 0.001), as well as the daily insulin-requirement (pooled-estimate − 2.027; 95%CI (− 3.32, − 0.733); p = 0.002). On
the contrary, UCB was found to be uniformly ineffective; HbA1c% (pooled-estimate − 0.091, 95%CI (− 0.454, 0.271);
p = 0.622), significantly deteriorated C-peptide levels (pooled-estimate − 0.789; 95%CI (− 1.252, − 0.325); p < 0.001)
and daily insulin-requirement (pooled-estimate 0.916; 95%CI (0.247, 1.585); p = 0.007). All these observations
remained consistent when we carried out sub-group meta-analysis for T1DM and T2DM and also when we
compared patients who received WJ-MSCs or UCB to controls.
(Continued on next page)
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Conclusions: The results of our meta-analysis provide a clear evidence for the superior efficacy of WJ-MSCs over
UCB in DM. This sheds lights on the importance to consider banking of WJ-MSCs together with the well-established
routine UCB-banking, especially for those with family history of DM. Additionally, further clinical studies are required
to investigate therapeutic efficacy of selected/enriched UCB-derived cell populations with immunomodulatory/
regenerative potential in DM.
Keywords: Cell therapy, Diabetes mellitus, Regenerative medicine, Stem cell transplantation, Umbilical cord blood,
Wharton’s jelly mesenchymal stem cells

Background
Diabetes mellitus (DM) is a terribly growing epidemic,
currently affecting about 463 million people worldwide,
with expected rise to 700 million by the year 2045 [1]. It
is the most prevalent metabolic disease, in which insulin
secreting β cells are damaged to various extents. Different etiologies and interfering factors exist for each of
type 1 and type 2 DM (T1DM and T2DM), the most
famous well-known types [2, 3]. However, β cell dysfunction and hyperglycemia are disease hall-marks for
both types [4], and diabetic complications, as well as decreased life quality and increased mortality are unfortunately inevitable in most cases [5, 6]. Accordingly, there
is an urgent need to develop novel therapeutic modalities which would help not only to manage the disease,
but also hopefully provide a real cure for DM. Regenerative medicine and stem cell therapy opened new avenues
and ignited much hope for patients with DM over the
past few years [7].
Actually, more than couple of decades ago, stem cells
were thought to have great therapeutic potential and to
be the next frontier in medicine. However, the ethical
concerns surrounding embryonic stem cells (ESCs) represented a huge obstacle in the field of stem cell research [8]. This sparked much interest in exploring
other alternative sources for stem cells. In fact, various
types of stem cells have been investigated regarding their
therapeutic potential for DM in the preclinical as well as
clinical settings [9]. Interestingly, among the various
sources of stem cells, the umbilical cord (UC) has
proved to be a unique source, providing several advantages over other sources. Most importantly, UC-derived
stem cells are readily available and can be obtained noninvasively during the process of delivery. Moreover, their
banking potential adds a lot to their importance for regenerative medicine [10, 11].
Basically, in the early 1970s, the umbilical cord blood
(UCB) was reported to be a rich source of hematopoietic
stem cells (HSCs) [12]. Later on, the discovery that
Wharton’s jelly (WJ)/UC tissue can indeed provide a
promising source of mesenchymal stem cells (MSCs)
was first highlighted in the early 1990s of the last century [13]. UCB has also been reported as a source of

MSCs, but to a much lesser extent than UC-tissue [14].
It is noteworthy here that MSCs have made their mark
as a potential weapon in various regenerative medicine
applications over the past years, and many of their exceptional characteristics such as immuno-modulatory effects, as well as differentiation potential down various
lineages have been revealed [15].
Apart from stem cell transplantation, UCB has recently been employed in a relatively recent intervention
for treating DM, known as “Stem Cell Educator” therapy.
Briefly, during that intervention, mononuclear cells
(MNCs) isolated from the patient’s whole blood are cocultured with adherent UCB-derived stem cells and then
afterwards returned back to the patient’s blood circulation. Such intervention is currently in phase I/II clinical
trials to assess both its efficacy and safety to improve insulin resistance and treat DM [16–18].
In fact, several previous meta-analyses concluded the
safety as well as therapeutic efficacy of stem cell therapy
in DM. Nevertheless, published meta-analyses mostly
combined studies which applied MSCs derived from
various sources including the bone marrow-MSCs,
placenta-MSCs, as well as WJ-MSCs together [9, 19, 20],
and some also combined UCB together with peripheral
blood mononuclear cells (PB-MNCs) [21], or included
studies which employed UCB transplantation, together
with those employing “stem cell educator” therapy [22].
While others pooled all different types of stem cell therapies together including UCB, WJ-MSCs, as well as
HSCs and other types of MSCs [23]. Additionally, previously, we compared the therapeutic effect of WJ-MSCs
and UCB-derived MSCs in streptozotocin-induced diabetic rats. Interestingly, we found that WJ-MSCs can
better control hyperglycemia in diabetic rats in vivo and
also better differentiate into insulin producing cells
in vitro, as compared with UCB-MSCs [24].
Accordingly, in the current study, we thought to carry
out a rather focused meta-analysis to carefully assess the
therapeutic efficacy of UC-derived stem cell transplantation, namely WJ-MSCs and UCB, and compare their
putative therapeutic potential and clinical outcome for
both types of DM. We decided to evaluate their therapeutic efficacy based on assessing glycemic control
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status (reflected on HbA1c%) and β cell function
(reflected on C-peptide levels) after receiving stem cell
transplantation compared to baseline values, as well as
assessing these same parameters in patients who received intervention compared to those who did not receive it in randomized/non-randomized controlled
clinical trials. To the best of our knowledge, this is the
first study carried out to compare the clinical efficacy of
these two UC-derived stem cells with banking potential
in DM.

Methods
Search strategy and data mining

A computer-based extensive literature review was conducted on databases such as Scopus, Web of Science,
MEDLINE/PubMed, Cochrane library for clinical trials,
and the public clinical trials database (ClinicalTrials.gov).
This searching and screening was done on databases
until the 26th of April 2020. Generally, the database was
searched using the following key words: (umbilical cord
OR Wharton jelly mesenchymal stem cells OR cord
blood) AND (diabetes mellitus OR hyperglycemia). The
term “stem cell transplantation” was also used when
searching Cochrane library and Scopus database, and the
MeSH term “cord blood stem cell transplantation” was
additionally used while searching MEDLINE/PubMed.
In more detail, for MEDLINE/PubMed, first we ran
the following query: ((Wharton jelly mesenchymal stem
cells) OR (cord blood stem cell transplantation [MeSH
Terms])) OR (umbilical cord [MeSH Terms]), and afterwards the following query: (diabetes mellitus [MeSH
Terms]) OR (hyperglycemia [MeSH Terms]), then
looked for the common reports between the two search
queries as follows: ((diabetes mellitus [MeSH Terms])
OR (hyperglycemia [MeSH Terms])) AND (((Wharton
jelly mesenchymal stem cells) OR (cord blood stem cell
transplantation [MeSH Terms])) OR (umbilical cord
[MeSH Terms])). The retrieved reports from all databases were downloaded to citation manager, which
helped us to identify and exclude duplicates, as well as
review articles and irrelevant reports. Finally, regarding
the search on public clinical trials database, “diabetes
mellitus” as a disease and “umbilical cord” as an additional search term/intervention was used. While searching, we did not specify any restrictions regarding the
article type, and we also checked all relevant published
meta-analyses and their reference lists.
The selection of studies/inclusion criteria

Eligible studies included clinical trials in which the
therapeutic efficacy of UC-derived SC transplantation
(WJ-MSCs or UCB) was assessed in human subjects.
Both randomized/non-randomized controlled and selfcontrolled clinical trials were eligible. Regarding
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randomized controlled trials, the therapeutic efficacy
was assessed in subjects who received stem cell transplantation compared to those who did not receive such
intervention as a control group. As for self-controlled
studies, the clinical efficacy was assessed via comparing
various parameters before and after receiving SC therapy. We did not place an inclusion restriction based on
the follow-up time after receiving the SC intervention.
The included studies had a follow-up period after stem
cell transplantation which varied from 6 months to 3
years.
Moreover, while searching, we found 4 studies which
employed UCB-derived stem cells in a relatively recent
intervention for treating DM, called “Stem Cell Educator
Therapy.” Briefly, in these studies, mononuclear cells
(MNCs) are isolated from the patient’s whole blood and
are co-cultured with adherent UCB-derived stem cells,
and afterwards, those educated autologous MNCs are
returned back to the patient’s blood circulation [16–18,
25]. For the current meta-analysis, we did not include
these “Stem Cell Educator” studies, because they did not
actually make an UC-derived stem cell transplantation
intervention, which is the focus of the current study.
Additionally, we excluded studies in which the subjects
had any additional pathology besides DM. Finally, it is
noteworthy that we did not place language restriction
during our initial screening/search, but for published
non-English language studies, we limited inclusion for
those having at least a detailed abstract in English language. Thus, exclusion criteria can be summarized as
animal studies, in vitro molecular studies, studies without SC transplantation intervention, studies in which the
subjects were suffering an additional pathology to DM,
and studies with incomplete/unavailable data. Figure 1
shows the flow diagram illustrating our search strategy
until reaching the selected included studies in our metaanalysis; this diagram was done according to the PRIS
MA statement guidelines [26]. In addition, the PRISMA
checklist for this meta-analysis study is presented in supplementary Table S1.
Data extraction and assessment of risk of bias

Data extraction was independently done by the two authors according to a standardized specified strategy. Any
disagreement was resolved through referring to the original publication and discussion/consensus. For the selected studies, we reported clinical trial type (i.e., either
randomized, non-randomized, or self-controlled trial),
the country of origin, the authors’ names, year of publication, the number of enrolled subjects, and their mean
age and duration of DM. We also collected data concerned with the type of DM, the type of UC-derived
stem cells employed (i.e., either WJ-MSCs or UCB), and
the count of injected cells, route of delivery, and
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Fig. 1 Flow diagram showing the screening and selection process of reports to be included in the meta-analysis

transplantation regimen, together with the total followup period after receiving the SC intervention. In
addition, we collected laboratory measurement data including HbA1c% levels, C-peptide levels, and the daily
insulin requirement, if available.
We initially did not place a restriction on the followup time after receiving the SC intervention. All the included studies had a follow-up period after stem cell
transplantation which varied from 6 months to 3 years.
Nevertheless, to reduce heterogeneity and in the same
time assess the long-term effect of SC intervention, for
those studies with extended follow-up period for 2 or 3
years, we selected the “1 year” time point, as our included time point for comparison in the current metaanalysis.
Any data which required digitalization was done using
the software (Plot Digitizer). Regarding data which were
presented as median (minimum–maximum) or median
(inter-quartile range), the means and standard deviation
were estimated for these studies, knowing their sample
size, using the Excel sheet and equations published by
Wan and co-workers [27].
The risk of bias in the enrolled randomized controlled
trials was assessed using the revised Cochrane risk of
bias evaluation tool (RoB-2) [28], where low, unclear
(having some concerns), or high degree of bias was
assigned for each of the following: randomization
process, deviation from intended intervention, missing
outcome data, measurement of the outcome, and

selection of the reported result. As for self-controlled
(before-after trials) and non-randomized studies, the risk
of bias was assessed using the ROBINS-I tool [29]. This
was further elucidated and visualized by the ROBVIS
tool [30] as shown in Supplementary Fig. S1 and S2.
Definition of outcome measures

Our primary outcome measures were HbA1c% and Cpeptide levels. HbA1c% is a crucial indicator for the extent of glycemic control, while C-peptide is a marker
providing an indication for β cell function. The daily insulin requirement was considered a secondary outcome
measure, also reflecting the state of the diabetic milieu
and β cell function. For those studies with extended
follow-up periods, we specified the “1 year” time point to
compare the specified outcome measures in the current
meta-analysis, as an attempt to reduce heterogeneity of
the enrolled studies.
Statistical analysis

The outcome measures HbA1c%, C-peptide levels, and
insulin daily requirement, as well as the study sample
size were fed into Open-Meta-Analyst to perform metaanalysis of the investigated studies and provide forest
plots (http://www.cebm.brown.edu/openMeta/). As the
studies in this meta-analysis vary in several aspects such
as the investigated populations, the route of stem cell
delivery, the dose/count of the injected cells, and the
intervention regimen, they do not meet the underlying
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assumption of a fixed-effects model in which only the
sampling error is the source of variability; hence, the
overall effect size was estimated using the randomeffects model, utilizing the Der Simonian−Laird method.
The random-effects model takes into account the variability between studies and was therefore adequate for
the purpose of this meta-analysis. Heterogeneity was
assessed using two parameters: the Cochran’s Q statistic
and the I2 index. The Q statistic indicates the presence
or absence of heterogeneity among a set of studies related to differences in the measurements, whereas the I2
index implies the degree of heterogeneity; observed
values up to 30 imply mild heterogeneity, 31–50 imply
moderate, while more than 50 imply marked
heterogeneity.
The standardized mean difference and a 95% confidence interval (CI) were calculated and represented in
the forest plot. It is noteworthy that we preferred to use
the standardized mean difference rather than the mean
difference in our meta-analysis to improve the homogeneity, since some studies were using different measurements for the specified outcome. Significance was
employed by the p value, where values < 0.05 were considered statistically significant. In case of having a single
study which weighed too much, in such a way raising
concerns regarding the results of the performed metaanalysis, a sensitivity of the study was evaluated using
the leave-one-out meta-analysis, to further assess the
outcome of such meta-analysis.
Finally, it is important to point here that the included
studies were initially classified into two major groups
based on the type of UC-SC intervention; WJ-MSCs or
UCB, and after wards when performing the metaanalysis, each of these groups was classified into 2 subgroups according to the type of DM while performing a
sub-group meta-analysis. As for the randomized controlled trials, due to their limited number, they were originally pooled together (T1DM and T2DM studies), and
the sub-group meta-analysis was afterwards done according to the type of intervention; either WJ-MSCs or
UCB.

Results
Search results and description of studies

As shown in Fig. 1, the initial databases’ search and electronic data mining revealed a total of 1372 records.
Within these, 186 duplicates were identified and excluded. Thus, a total of 1186 records were screened by
title to identify relevant studies. During this screening,
758 records were excluded for being irrelevant (such as
those concerned with gestational DM), and 329 citations
were excluded for being either review or meta-analysis
articles. Afterwards, the remaining 99 citations passed
through a further thorough investigation for eligibility.
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Of these, 66 citations were excluded for being either animal or in vitro molecular studies, 4 citations were excluded for being UC banking-related studies, and finally
10 citations excluded for being diabetic foot-related
studies. Next, the full text was carefully assessed for the
remaining 19 citations. In that phase, 8 citations were
further excluded for the following reasons; 4 studies for
being a stem-cell educator study in which stem cell
transplantation was not applied as an intervention [16–
18, 25], 1 study for having an additional pathology to
DM [31], and finally 3 studies were excluded due to lack
of data [32–34]. Thus, conclusively, 11 eligible clinical
trials were identified and included in the current metaanalysis study.
The characteristics of the 11 eligible included studies
are presented in Table 1. When considering the country
of origin of these studies, 6 studies came from China, 4
from the USA, and 1 from Germany. These 11 studies
included a total of 246 diabetic patients; 6 studies included patients with T1DM (142 patients, including 50
controls), and 5 studies included patients with T2DM
(104 patients, including 36 controls). When considering
the design of these studies, we found 5 of them were
randomized controlled trials [35, 36, 39–41], 1 study was
a non-randomized controlled trial [42], and 5 studies
were self-controlled (before-after) clinical studies [37,
38, 43–45].
When considering the type of UC-derived stem cell
intervention, we found 6 studies (172 patients, including
71 controls) which applied WJ-MSCs either through
intravenous and/or intra-pancreatic infusion. Of these, 3
studies applied WJ-MSCs solely as their therapeutic
intervention for T2DM, 1 study applied WJ-MSCs solely
for T1DM, 1 study applied WJ-MSCs plus bone
marrow-derived mononuclear cells for T1DM, and 1
study applied WJ-MSCs plus Liraglutide for T2DM. On
the other hand, we found 5 studies (74 patients, including 15 controls) which applied UCB also via intravenous
or intra-pancreatic infusion. Of these, 3 studies applied
UCB solely, and 1 study applied UCB followed by vitamin D and docosahexaenoic acid (DHA) for T1DM, and
a single study applied UCB for T2DM. The total followup period after the SC transplantation ranged from 6
months to 3 years.
When assessing the risk of bias in these 11 included
studies, the 5 randomized controlled trials were assessed
by Cochran’s RoB2 tool. As illustrated in Supplementary
Fig. S1, they all showed a low to moderate risk of bias.
The noticed concerns were mostly attributed to the
randomization process, as well as lack of information regarding the concealment methods, and avoiding deviation from intended intervention. The risk of bias for
the non-randomized as well as self-controlled studies
was assessed by the ROBINS-I tool. As shown in
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Table 1 Characteristics of the study populations in the clinical studies enrolled in the meta-analysis
Name of the
study

Type
of
DM

Type of
intervention

Mean
age
(year)

Mean
duration
of DM

Total follow-up Country
period (year)

Reference

Hu et al., 2013

T1DM WJ-MSCs
(Allogenic)

1.5–3.2 × 107 IV – Parenteral SC group: 15 (9/6)
solution
Control group: 14 (8/6)
Twice, 4
weeks interval

17.6 ± 8.7
18.2 ± 7.9

Newly
onset not more
than 6
months

2

China

[35]

Hu et al., 2016

T2DM WJ-MSCs
(Allogenic)

1 × 106/kg

IV – Parenteral SC group: 31 (17/14)
solution
Control group: 30 (16/14)
Twice, 4
weeks interval

52.4 ± 4.9
53.2 ± 8.2

8.9 ± 5.7
year
8.3 ± 6.07
year

3

China

[36]

Liu et al., 2014 T2DM WJ-MSCs
(Allogenic)

1 × 106/kg

1 IV and 1 IPA
endovascular
injection, 5
days interval

SC group: 22 (15/7)

52.9 ± 10.5 8.7 ± 4.3
year

1

China

[37]

Guan et al.,
2015

1 × 106/kg

IV infusion
Twice, 2
weeks interval

SC group: 6 (6/0)

40.5 ± 3.76 3.6 ± 1.9
year

2

China

[38]

Cai et al., 2016 T1DM WJ-MSCs
(Allogenic)
plus BMMNCs
(Autologous)

1.1 × 106/kg
WJ-MSCs
plus
106.8 × 106/
kg BMMNCs

IPA (Once)

SC group: 21 (9/12)
Control group: 21 (11/10)

18.3 ± 5.2
20.4 ± 3.7

9.2 ± 4.8
year
7 ± 3.3
year

1

USA

[39]

Chen et al.,
2016 (Article
Chinese –
English
Abstract)

T2DM WJ-MSCs
(Allogenic)
plus
Liraglutide

1 × 106
cells/kg

IPA infusion
on the first
day followed
by IV infusion
on the 8th,
15th and
22nd day

SC group: 6 (NA)
Control group: 6 (NA)

NA

Not more
than 10
years

6 months

China

[40]

Haller et al.,
2013

T1DM UCB
(Autologous)
plus vitamin
D + DHA

1.1 × 107
cells/kg

IV (Once)

SC group: 10 (8/2)
Control group: 5 (3/2)

6–7

Newly
1
diagnosed

USA

[41]

Giannopoulou
et al., 2013

T1DM UCB
(Autologous)

3.89 × 107
cells/kg

IV (Once)

SC group: 7 (5/2)
Control group: 10 (4/6)

3.3 ± 1.3
6.9 ± 2.3

Newly
1
diagnosed

Germany [42]

Haller et al.,
2011

T1DM UCB
(Autologous)

1.88 × 107
cells/kg

IV (Once)

SC group: 24 (10/14)

5.1 ± 2.8

0.32 ±
0.26 years

2

USA

[43]

Haller et al.,
2009

T1DM UCB
(Autologous)

1.5 × 107
cells/kg

IV (Once)

SC group: 15 (8/7)

5.2 ± 3.4

6 months

1

USA

[44]

Tong et al.,
2013

T2DM UCB
(Allogenic)

2.88 × 106
cells/kg

IPA (Once)

SC group: 3 (3/0)

40.7 ± 5.5

6.6 ± 5.6
year

6 months

China

[45]

T2DM WJ-MSCs
(Allogenic)

Injected
cells’ count

Route of
delivery

Number of patients
N (Males/Females)

Abbreviations: WJ-MSCs Wharton’s jelly mesenchymal stem cells, UCB umbilical cord blood, BM-MNCs bone marrow-mononuclear cells, T1DM type 1 diabetes
mellitus, T2DM type 1 diabetes mellitus, IV intravenous, IPA intra-pancreatic artery, and DHA docosahexaenoic acid

Supplementary Fig. S2, they mostly had a relatively low
risk of bias; nonetheless, some concerns were found regarding confounding factors.
The outcome of WJ-MSC therapy in DM

Transplantation of allogenic WJ-MSCs was applied in 6
studies (172 patients, including 71 controls) either
through intravenous and/or intra-pancreatic infusion. For
the purpose of assessing WJ-MSC therapeutic efficacy, we
decided to make meta-analysis for the specified outcomes
such as HbA1c% and C-peptide levels before and after SC
intervention and also to compare these outcome measures
between patients who received the intervention and those
who did not receive it in the randomized/non-randomized
controlled trials. It is noteworthy that data at the baseline
(before SC intervention) compared to that after SC

intervention was available in only 5 of the included studies
which applied WJ-MSCs. Accordingly, we only included
these 5 studies in the meta-analysis when assessing outcome measures before and after SC therapy.
First, regarding HbA1c% levels, these were assessed
after 1 year of WJ-MSC transplantation compared to respective baseline values in 5 included studies (2 T1DM
studies—36 patients, and 3 T2DM studies—59 patients).
Table 2 shows the mean values of HbA1c% before and
after receiving WJ-MSCs therapy. It is noteworthy that
the mean values of HbA1c% were consistently decreased
in all the studies after 1 year of SC-therapy compared to
the baseline levels. The overall meta-analysis was statistically significant with a pooled estimate of − 1.085, 95%
CI (− 1.513, − 0.657), p value <0.001, as well as a moderate heterogeneity with I2 score 45%.
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Table 2 Summary of the meta-analyses done for enrolled subjects before and after receiving umbilical cord-derived stem cell
transplantation
Study name and year

Number
of
subjects

After SC
Mean

SD

Number
of
subjects

Before SC
Mean

SD

Study
Weight
(%)

SMD

Lower
CI

Upper
CI

Type
of
DM

Type of
UC-SC

HbA1c%
Hu et al., 2013

15

6.100

1.100

15

6.850

2.200

19.9

− 0.420

− 1.143

0.304

T1DM

WJ-MSCs

Hu et al., 2016

31

6.000

0.700

31

7.670

1.230

25.1

− 1.648

− 2.224

− 1.072

T2DM

WJ-MSCs

Liu et al., 2014

22

7.000

0.600

22

8.200

1.690

23.3

− 0.929

− 1.551

− 0.307

T2DM

WJ-MSCs

Guan et al., 2015

6

6.500

1.850

6

8.550

1.450

9.7

− 1.138

− 2.358

0.082

T2DM

WJ-MSCs

Cai et al., 2016

21

7.500

1.000

21

8.600

0.810

22.1

− 1.186

− 1.842

−0.530

T1DM

WJ-MSCs

Haller et al., 2013

10

7.100

1.290

10

7.067

1.290

17.1

0.024

−0.852

0.901

T1DM

UCB

Giannopoulou et al., 2013

7

7.250

0.440

7

7.025

0.840

11.8

0.314

− 0.740

1.368

T1DM

UCB

Haller et al., 2011

24

7.200

0.870

24

7.430

1.497

40.9

− 0.185

− 0.752

0.382

T1DM

UCB

Haller et al., 2009

15

7.067

0.980

15

7.130

1.799

25.6

− 0.042

− 0.758

0.673

T1DM

UCB

Tong et al., 2013

3

7.170

0.420

3

10.530

3.720

4.5

− 1.013

− 2.713

0.687

T2DM

UCB

Hu et al., 2013 a

15

1.350

0.230

15

0.850

1.820

20.3

0.375

− 0.347

1.097

T1DM

WJ-MSCs

a

31

2.660

0.330

31

1.750

0.640

23.2

1.765

1.178

2.352

T2DM

WJ-MSCs

Liu et al., 2014 a

22

1.860

1.000

22

1.290

0.830

22.8

0.609

0.005

1.214

T2DM

WJ-MSCs

C-peptide levels (ng/ml)

Hu et al., 2016

6

2.120

1.250

6

1.030

0.300

12.1

1.107

− 0.109

2.322

T2DM

WJ-MSCs

Cai et al., 2016 a

21

0.060

0.030

21

0.030

0.020

21.7

1.154

0.501

1.808

T1DM

WJ-MSCs

Haller et al., 2013 b, *

10

0.160

0.180

10

0.360

0.240

19.1

− 0.903

− 1.823

0.017

T1DM

UCB

Giannopoulou et al., 2013 b

7

0.390

0.388

7

0.945

0.540

13.9

− 1.105

− 2.230

0.020

T1DM

UCB

Haller et al., 2011

24

0.400

0.550

24

1.190

0.800

33.2

− 1.132

− 1.741

− 0.523

T1DM

UCB

Haller et al., 2009 b

15

0.690

0.850

15

1.220

1.090

26.6

− 0.528

− 1.256

0.200

T1DM

UCB

3

2.040

1.050

3

1.300

0.320

7.1

0.761

− 0.896

2.418

T2DM

UCB

a

Guan et al., 2015

b

Tong et al., 2013

a

Insulin daily requirement (IU/Kg/day)
Hu et al., 2013 #

15

20.700

11.100

15

37.800

4.600

20.1

− 1.958

− 2.829

− 1.088

T1DM

WJ-MSCs

Hu et al., 2016 #

31

12.000

3.000

31

45.900

8.900

19.4

− 5.040

− 6.058

− 4.023

T2DM

WJ-MSCs

Liu et al., 2014

22

0.230

0.190

22

0.490

0.220

20.9

− 1.242

− 1.888

− 0.597

T2DM

WJ-MSCs

Guan et al., 2015

6

0.280

0.350

6

0.430

0.220

18.8

− 0.473

− 1.621

0.674

T2DM

WJ-MSCs

Cai et al., 2016

21

0.600

0.200

21

0.900

0.200

20.8

− 1.472

− 2.154

− 0.790

T1DM

WJ-MSCs

Haller et al., 2013

10

0.640

0.150

10

0.340

0.198

19.5

1.636

0.623

2.648

T1DM

UCB

Giannopoulou et al., 2013

7

0.790

0.410

7

0.660

0.470

18.8

0.276

− 0.777

1.329

T1DM

UCB

Haller et al., 2011

24

0.680

0.200

24

0.370

0.230

26.8

1.415

0.782

2.047

T1DM

UCB

Haller et al., 2009

15

0.660

0.180

15

0.390

0.280

24.0

1.116

0.347

1.885

T1DM

UCB

Tong et al., 2013

3

0.320

0.210

3

0.525

0.130

10.9

− 0.937

− 2.622

0.749

T2DM

UCB

a

Fasting C-peptide
b
Stimulated peak C-peptide
*
Measuring unit; pmol/L
#
Measuring unit; IU/day

When considering C-peptide levels which reflect the
endogenous insulin synthesis and secretion, we compared the baseline fasting C-peptide levels to those reported 1 year after WJ-MSC transplantation for all the
included 5 studies. As shown in Table 2, the mean Cpeptide levels were consistently elevated in all the included studies after 1 year of WJ-MSC transplantation

compared to their respective baseline levels. The metaanalysis revealed an overall pooled estimate of 1.008,
95% CI (0.475, 1.541), p < 0.001, and marked heterogeneity with I2 score 64%.
To gain further insight into the effect of WJ-MSC
transplantation, we carried out a meta-analysis for the
daily insulin requirement reported in the included
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studies at the baseline and after 1 year of WJ-MSC
transplantation. This will indirectly reflect the status
of the diabetic milieu and endogenous insulin synthesis. Interestingly, the daily insulin requirement was
found to be uniformly decreased in all the investigated studies after WJ-MSC therapy compared to respective baseline values as shown in Table 2.
Additionally, in one of these studies, 3 out of 15
T1DM patients became completely insulin independent at the end of the 2-year follow-up period, and in
8 of the remaining 12 patients, the insulin daily dosage was reduced by more than 50% of the initial daily
requirement at the baseline [35]. Likewise, Liu et al.
reported that insulin suspension occurred for nearly
41% of the T2DM patients who were receiving insulin
therapy. This occurred within a time frame of 2 to 6
months after WJ-MSC transplantation, and these patients remained insulin-free for a mean time of 9
months until the last follow-up of the study [37]. The
same observation was also reported by Hu and coworkers; 32% of the T2DM patients who received WJMSC transplantation became insulin-free within a
period ranging from 3 to 11 months after receiving
WJ-MSC infusion and remained insulin-free for a
mean period of 12.5 ± 6.8 months [36]. The overall
meta-analysis for the daily insulin requirement in the
included studies before and after 1 year of receiving
SC therapy showed a pooled estimate of − 2.027, 95%
CI (− 3.32, − 0.733), p = 0.002, with I2 score of 92%,
implying a marked degree of heterogeneity.
The outcome of WJ-MSC therapy in T1DM

When we carried out sub-group meta-analysis for the
included studies in Table 2, based on the type of DM, as
shown in Fig. 2a, the effect of WJ-MSCs on HbA1c%
remained significant for T1DM. The analysis showed a
pooled estimate of − 0.819, 95% CI (− 1.569, − 0.068),
p = 0.033, and I2 score 58%. Additionally, as shown in
Fig. 3a, the effect of WJ-MSCs on C-peptide levels
remained significant for T1DM, and the analysis revealed a pooled estimate of 0.781, 95% CI (0.017, 1.544),
p = 0.045. Nonetheless, a relatively marked degree of heterogeneity was observed with an I2 score of 59%. As for
the daily insulin requirement, as shown in Fig. 4a, in the
sub-group analysis, the I2 score decreased to 0% for
T1DM studies, with a significant pooled estimate of −
1.657, 95% CI (− 2.193, − 1.12), p < 0.001.
The outcome of WJ-MSC therapy in T2DM

When we carried out sub-group meta-analysis for the
included studies in Table 2, based on the type of DM, as
shown in Fig. 2a, the effect of WJ-MSCs on HbA1c%
remained significant for T2DM. The analysis revealed a
pooled estimate of − 1.281, 95% CI (− 1.781, − 0.782),
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p < 0.001, and mild heterogeneity with I2 score 29%.
Moreover, as shown in Fig. 3a, the effect of WJ-MSCs
on C-peptide levels remained significant for T2DM in
the sub-group analysis which revealed a pooled estimate
of 1.171, 95% CI (0.349, 1.993), p = 0.005. However, a
relatively marked degree of heterogeneity was still observed with an I2 score of 72%. Regarding the daily insulin requirement, as shown in Fig. 4a, the subgroup metaanalysis revealed a non-significant pooled estimate; −
2.25, 95% CI (− 4.812, 0.313), p = 0.085. This was also associated with a very high degree of heterogeneity among
the 3 included T2DM studies, I2 score 96%.
Accordingly, all the performed subgroup metaanalyses imply better glycemic control after WJ-MSC
therapy in both types of DM.
The outcome of UCB therapy in DM

Transplantation of UCB was applied in 5 studies (74 patients, including 15 controls) either through intravenous
infusion in the included 4 T1DM studies [41–44] or
intra-pancreatic infusion for the single included T2DM
study [45]. Like WJ-MSCs, for the purpose of assessing
UCB therapeutic efficacy, we decided to make metaanalysis for the specified outcomes HbA1c% and Cpeptide levels before and after SC intervention and also
to compare these outcome measures between patients
who received the intervention and those who did not receive it in the randomized/non-randomized controlled
trials.
First, regarding HbA1c% levels, these were assessed
after 1 year of UCB transplantation compared to respective baseline values in the 5 included studies (4 T1DM
studies—71 patients, and 1 T2DM studies—3 patients).
Table 2 shows mean values of HbA1c% before and after
receiving UCB transplantation. It is noteworthy that the
mean values of HbA1c% were consistently nearly comparable in all the T1DM studies after 1 year of SC therapy compared to the baseline levels, and HbA1c% levels
were decreased in T2DM patients who received UCB
intervention; however, this seemed to be statistically
non-significant in the meta-analysis; 95% CI (− 2.713,
0.687). The overall meta-analysis for all the included 5
studies was statistically non-significant with a pooled estimate of − 0.091, 95% CI (− 0.454, 0.271), p value 0.622,
as well as negligible heterogeneity with I2 score 0%.
When considering C-peptide levels, we compared the
baseline fasting C-peptide levels to those reported 1 year
after UCB transplantation for all the included 5 studies.
As shown in Table 2, UCB seems to be consistently ineffective regarding improving C-peptide levels. When having a closer look on the data, we will find the mean Cpeptide levels in fact decreased in all the T1DM studies
in those patients who received UCB intervention compared to their baseline levels. As for the single T2DM
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Fig. 2 Forest plots showing HbA1c% levels before and after application of umbilical cord-derived stem cell transplantation. a Comparison of
HbA1c% levels at baseline and after WJ-MSC intervention in both T1DM and T2DM and b comparison of HbA1c% levels at baseline and after
UCB intervention in both T1DM and T2DM. The random-effects meta-analysis model (Der Simonian−Laird method) was used. The ends of the
horizontal bars denote a 95% CI. The diamond gives the overall standardized mean difference (pooled estimate) for the combined results of all
included trials

study, UCB seems to have resulted in a slight yet nonsignificant elevation of C-peptide levels. The metaanalysis revealed an overall pooled estimate of − 0.789,
95% CI (− 1.252, − 0.325), p < 0.001, and mild heterogeneity with I2 score 26%.
As for the daily insulin requirement, we carried out a
meta-analysis for the included studies to assess the variation of insulin daily dosage at the baseline and after 1
year of UCB transplantation. In fact, in agreement with
the reported results concerned with HbA1c% and Cpeptide levels, the daily insulin requirement was found
to be uniformly increased in all the included T1DM
studies and showed a slight decrease in the included
T2DM study as shown in Table 2. The overall metaanalysis for the daily insulin requirement in the included
studies before and after 1 year of receiving UCB therapy

showed a pooled estimate of 0.916, 95% CI (0.247,
1.585), p = 0.007, with I2 score of 60%, implying a
marked degree of heterogeneity. These data imply the
lack of improvement on insulin daily requirement and
the relatively poor therapeutic efficacy of UCB in this
regard.
The outcome of UCB therapy in T1DM

When we carried out sub-group meta-analysis for the
included studies in Table 2, based on the type of DM, as
shown in Fig. 2b, the effect of UCB on HbA1c%
remained non-significant for T1DM with a pooled estimate of − 0.047, 95% CI (− 0.418, 0.324), p = 0.803. This
implies that UCB does not have a significant beneficial
effect over glycemic control in T1DM. Afterwards, as
shown in Fig. 3b, in the sub-group analysis to assess the
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Fig. 3 Forest plots showing C-peptide levels before and after application of umbilical cord-derived stem cell transplantation. a Comparison of Cpeptide levels at baseline and after WJ-MSCs intervention in both T1DM and T2DM and b comparison of C-peptide levels at baseline and after
UCB intervention in both T1DM and T2DM. The random-effects meta-analysis model (Der Simonian−Laird method) was used. The ends of the
horizontal bars denote a 95% CI. The diamond gives the overall standardized mean difference (pooled estimate) for the combined results of all
included trials

effect of UCB on C-peptide levels of T1DM patients, the
analysis revealed a pooled estimate of − 0.913, 95% CI
(− 1.304, − 0.523), p < 0.001, and a negligible degree of
heterogeneity with I2 score 0%, implying the consistency
of the lack of efficacy, and deteriorating levels of Cpeptide despite receiving UCB therapy as shown in
Table 2. Regarding the daily insulin requirement, the
sub-group analysis as shown in Fig. 4b revealed a relatively low heterogeneity with an I2 score of 28%, and a
significant pooled estimate of 1.173, 95% CI (0.682,
1.664), p < 0.001. This is consistent with the increasing
daily insulin requirements shown in Table 2 in the enrolled T1DM patients despite receiving UCB therapy.
These data imply the lack of improvement of insulin
daily requirement and the relatively overall poor therapeutic efficacy of UCB in T1DM.

The outcome of UCB therapy in T2DM

When we carried out sub-group meta-analysis for the
included studies in Table 2, based on the type of DM, as
shown in Fig. 2b, for T2DM, a single study was included
and showed a pooled estimate of − 1.013, 95% CI (−
2.713, 0.687). This implies that UCB does not have a significant beneficial effect over glycemic control in T2DM.
Afterwards, as shown in Fig. 3b, in the sub-group analysis to assess the effect of UCB on C-peptide levels of
T2DM patients, the analysis revealed a pooled estimate of 0.761, 95% CI (− 0.896, 2.418). Regarding the
daily insulin requirement, the sub-group analysis as
shown in Fig. 4b revealed a non-significant pooled estimate of − 0.937, 95% CI (− 2.622, 0.749). All these
data imply the lack of improvement on insulin daily
requirement.
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Fig. 4 Forest plots showing daily insulin requirement before and after application of umbilical cord-derived stem cell transplantation. a
Comparison of daily insulin requirement at baseline and after WJ-MSCs intervention in both T1DM and T2DM and b comparison of daily insulin
requirement at baseline and after UCB intervention in both T1DM and T2DM. The random-effects meta-analysis model (Der Simonian−Laird
method) was used. The ends of the horizontal bars denote a 95% CI. The diamond gives the overall standardized mean difference (pooled
estimate) for the combined results of all included trials

Comparing the therapeutic outcome of WJ-MSCs and UCB
in randomized/non-randomized controlled trials

Afterwards, we carried out meta-analyses for HbA1c%
and C-peptide levels to assess the overall effect between
the patients who received neither WJ-MSCs nor UCB
transplantation and those who received SC therapy (after
1 year of receiving WJ-MSCs or UCB intervention). In
that analysis, 6 trials were included; 2 trials applied UCB
for T1DM (32 patients, including 15 controls), 2 trials
applied WJ-MSCs for T1DM (71 patients, including 35
controls), and 2 trials applied WJ-MSCs for T2DM (73
patients, including 36 controls). First regarding HbA1c%
levels, as shown in Fig. 5a, the subgroup meta-analysis
based on the type of SC-therapy (WJ-MSCs or UCB) revealed a significant overall effect for WJ-MSCs with a
pooled estimate of − 1.317 with 95% CI (− 1.688, −

0.947), p < 0.001; this was also accompanied by a negligible degree of heterogeneity with 3% I2 score. Such a
significant overall effect was lacking for UCB, which
showed a pooled estimate of − 0.1, 95% CI (− 0.819,
0.62), p = 0.786, and 0% I2 score. It is indeed noteworthy
that HbA1c% levels were uniformly lower in the SC
therapy group compared to the control group in all WJMSC studies, while these levels were nearly comparable
between the two groups in the UCB studies, as shown in
Table 3.
Second, regarding C-peptide levels, as shown in Fig. 5b,
the subgroup meta-analysis revealed a significant overall
effect for WJ-MSCs with a pooled estimate of 2.019, 95%
CI (0.958, 3.08), p < 0.001. Nonetheless, this was accompanied by a marked degree of heterogeneity with 84% I2
score. As for UCB, a non-significant overall effect was
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Fig. 5 Forest plots comparing the HbA1c% and C-peptide levels between stem cell therapy and control group. a Comparison of HbA1c% levels
after applying WJ-MSCs or UCB in patients with DM and b comparison of C-peptide levels after applying WJ-MSCs or UCB in patients with DM.
The random-effects meta-analysis model (Der Simonian−Laird method) was used. The ends of the horizontal bars denote a 95% CI. The diamond
gives the overall standardized mean difference (pooled estimate) for the combined results of all included trials

observed with a pooled estimate of − 0.587, 95% CI (−
1.324, 0.151), p = 0.119, and 0% I2 score which implies
the absence of heterogeneity. As shown in Table 3, it is
important to note that when considering WJ-MSC studies, C-peptide levels were uniformly elevated in SC therapy group compared to the control group. However, the
opposite scenario was observed in the case of UCB
studies.

Discussion
In the current meta-analysis study, we attempted to
evaluate the therapeutic efficacy of both types of UCderived stem cells with banking potential, namely WJMSCs and UCB, for diabetes mellitus. The overall results
of the carried out meta-analyses provide a moderate
quality evidence suggesting the better therapeutic

outcome of WJ-MSCs over UCB in both T1DM and
T2DM. During the past few years, the therapeutic potential of both WJ-MSCs and UCB for DM has ignited great
interest [46, 47]. In addition, several meta-analysis studies recently reported the clinical efficacy of various types
of stem cells for treating DM with several degrees of
therapeutic efficacy [9, 48]. However, to the best of our
knowledge, the current meta-analysis is the first one focusing on those stem cells derived from UC and assessing their reported therapeutic effects in both types of
DM. We demonstrated that WJ-MSC transplantation
could improve HbA1c%, as well as C-peptide levels in
both T1DM and T2DM, while UCB uniformly lacked
such beneficial effects.
In order to assess the therapeutic outcome of UCderived stem cells for DM, first we classified the eligible
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Table 3 Summary of the meta-analyses done to assess therapeutic efficacy of umbilical cord-derived stem cell transplantation in
subjects who received intervention compared to control subjects who did not receive that intervention
Study name and year

Number
of
subjects

SC group

Number
of
subjects

Control group

Mean

SD

Hu et al., 2013

15

6.100

Hu et al., 2016

31

6.000

Study
weight

SMD

Lower
CI

Upper
CI

Type
of
DM

Type of
UC-SC

Mean

SD

1.100

14

7.400

0.700

30

7.100

1.900

18.7

− 0.821

− 1.580

− 0.063

T1DM

WJ-MSCs

0.800

22.5

− 1.446

− 2.010

− 0.883

T2DM

WJ-MSCs

HbA1c%

Cai et al., 2016

21

7.500

1.000

21

8.800

0.900

20.4

− 1.341

− 2.010

− 0.671

T1DM

WJ-MSCs

Chen et al., 2016

6

6.820

0.530

6

7.820

0.310

9.6

− 2.125

− 3.541

− 0.710

T2DM

WJ-MSCs

Haller et al., 2013

10

7.100

1.290

5

7.400

0.400

13.5

− 0.258

− 1.335

0.820

T1DM

UCB

Giannopoulou et al., 2013

7

7.250

0.440

10

7.225

1.070

15.2

0.027

− 0.939

0.993

T1DM

UCB

Hu et al., 2013 a

15

1.350

0.230

14

0.810

0.300

16.9

1.973

1.085

2.861

T1DM

WJ-MSCs

a

31

2.660

0.330

30

1.670

0.250

17.3

3.331

2.555

4.106

T2DM

WJ-MSCs

Cai et al., 2016 a

21

0.060

0.030

21

0.030

0.020

17.7

1.154

0.501

1.808

T1DM

WJ-MSCs

C-peptide levels (ng/ml)

Hu et al., 2016

Chen et al., 2016

c

6

0.700

0.380

6

0.220

0.130

15.4

1.560

0.267

2.852

T2DM

WJ-MSCs

Haller et al., 2013 b, *

10

0.163

0.181

5

0.207

0.211

16.2

− 0.217

− 1.293

0.859

T1DM

UCB

Giannopoulou et al., 2013 b

7

0.390

0.388

10

1.032

0.800

16.5

− 0.914

− 1.928

0.099

T1DM

UCB

a

Fasting C-peptide
b
Stimulated peak C-peptide
c
Stimulated early phase C-peptide secretion function ΔCP30/ΔG30
*
Measuring unit; pmol/L

included studies based on the type of intervention, either
WJ-MSCs or UCB. Afterwards, we carried out subgroup meta-analyses for the studies employing each cell
type based on the type of DM to assess the effect of such
intervention on HbA1c%, C-peptide levels, and the daily
insulin requirement, in patients before and after receiving SC therapy, and also in patients who received SC
therapy compared to controls who did not receive such
intervention. Six studies were included for WJ-MSCs in
these analyses; 2 T1DM and 4 T2DM studies. As for
UCB, 5 studies were included; 4 T1DM and 1 T2DM.
When assessing the risk of bias within included studies
using Cochrane’s RoB-2 and ROBINS-I tools, generally
the included studies showed relatively low to moderate
risk. The reported concerns were mainly attributed to
randomization methods and ensuring concealment, as
well as blinding/masking of participants and reporting
personnel. In addition, some concerns aroused due to
co-intervention of WJ-MSCs together with autologous
BM-MSCs in one of the included studies [39], as well as
co-administration of vitamin D and docosahexaenoic
acid with the UCB intervention in another study [41].
First, regarding WJ-MSCs, we found that they caused
a significant decrease in HbA1c% levels compared to
both baseline pre-therapy values, as well as control
group patients who did not receive the intervention during the follow-up periods. This effect was consistent
among the included studies for both T1DM and T2DM,

with a minimal negligible degree of heterogeneity among
the included randomized controlled trials in the metaanalysis comparing those who received or did not receive the intervention after 1 year of WJ-MSC transplantation. As for C-peptide levels, fasting levels were
assessed in all the included studies employing WJ-MSCs,
except for a single randomized controlled trial, the stimulated early phase C-peptide secretion function ΔCP30/
ΔG30 was included [40]. That is one of the reasons why
we preferred to use the random-effects model and standardized mean difference in our analyses. The results of
our meta-analysis showed a significant improvement of
C-peptide levels compared to both baseline pre-therapy
values, as well as control group patients who did not receive the intervention, for both T1DM and T2DM.
However, this was associated with a marked degree of
heterogeneity, which raises some concerns regarding the
consistency of such effect and warrants further studies
to confirm it. Besides therapeutic efficacy and glycemic
control measures, it is important to point here that Hu
and co-workers also reported that WJ-MSC infusion significantly reduced the incidence of diabetic complications in T2DM. That notion was based on a 3-year
follow-up period and comparing the rate of incidence of
diabetic complications such as retinopathy, nephropathy,
and neuropathy between the group of patients who received WJ-MSC intervention and those who did not receive it [36].
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In fact, the previous observations come in perfect
agreement with our findings regarding the daily insulin
requirement assessment before and after receiving WJMSC transplantation in T1DM. The daily insulin requirement significantly decreased in patients after receiving WJ-MSC therapy, not only that, but also 3 out of
15 patients became insulin-free in one study [35]. As for
T2DM, the results of meta-analysis for the daily insulin
requirement were quite in-consistent. On the one hand,
non-significant pooled estimate was observed with a
marked degree of heterogeneity with 96% I2 score. On
the other hand, two of the included studies reported
insulin-suspension in 30–40% of the patients who received WJ-MSC transplantation [36, 37]. Such discrepancy might be at least partially attributed to the different
patients’ properties regarding the diabetes duration before receiving WJ-MSC intervention, as well as the different regimens used for WJ-MSC transplantation.
Generally, our meta-analysis was limited by the relatively
small sample size. Nevertheless, it is noteworthy that for
T1DM specifically, the studies of WJ-MSCs were very
limited, we only found two studies, and one of these applied WJ-MSCs together with bone marrow-derived
mono-nuclear cells (BM-MNCs) [39], so there are some
concerns regarding the bias of co-intervention. It is
noteworthy that we found an additional registered clinical trial currently recruiting patients in Vietnam to assess this same co-intervention of WJ-MSCs with
autologous BM-MNCs in T1DM, NCT03484741 [49].
Accordingly, given the reported safety of WJ-MSCs, further well-designed large scale studies are indeed warranted to confirm their therapeutic efficacy, especially
for T1DM. Luckily, we found two registered randomized
controlled trials in the USA (NCT04061746) and
Sweden (NCT03406585). These trials are currently
recruiting patients to assess the efficacy of allogenic WJMSCs in T1DM patients, with estimated completion
date by 2023 [49].
It is important to point here that all the studies
which applied WJ-MSCs employed allogenic SC therapy (without the application of immuno-suppressive
drugs), while in the case of UCB, all the studies
applied autologous SC therapy except Tong and coworkers who applied allogenic UCB in T2DM patients [45]. Such observation shed lights on the fact
that well-designed clinical studies to also assess the
efficacy of autologous WJ-MSCs for DM in the future are indeed warranted. This might be complicated by the lack of standardized cryo-preservation
protocols for WJ-MSCs, unlike UCB whose banking
procedures are well-established [50]. In fact, wellstandardized cryo-preservation/banking protocols for
GMP-compliant clinical grade WJ-MSCs are indeed
warranted and considered to be among the major
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challenges for successful translation of WJ-MSCs
from bench to bed-side [51].
When considering the results of our meta-analysis for
UCB effect on HbA1c% levels, it was found to be uniformly ineffective in both T1DM and T2DM. This observation was consistent among all the included studies
with negligible or nearly absent heterogeneity, which reflects the lack of efficacy on the glycemic control and
diabetic status in those patients who received the UCB
intervention. It is noteworthy that when assessing the effect of UCB transplantation on HbA1c%, the weight of
one of the studies was 40.9%. Accordingly, we carried
out a leave-one-out meta-analysis to exclude the study
of the highest weight [43]. However, this revealed the
same findings of the original meta-analysis as a further
confirmation for the lack of efficacy as shown in Supplementary Fig. S3. This comes in perfect agreement with
the consistent lack of improvement in C-peptide levels,
either in comparison to the baseline values (before receiving UCB infusion) or compared to those controls
who did not receive UCB transplantation. It is noteworthy here that for UCB studies, the stimulated peak
C-peptide levels were reported in all the T1DM studies
as an indication of insulin synthesis and C-peptide secretion, rather than the fasting levels [41–44]. As for the
single included T2DM, the fasting C-peptide levels were
reported and included in our meta-analysis [45]. Again,
that is why we preferred here to use the random-effects
model, as well as the standardized mean difference for
our meta-analysis.
Our analyses also revealed a consistent lack of improvement in the daily insulin requirement compared to
the baseline values before UCB therapy for both T1DM
and T2DM. It is important to point here that unlike WJMSCs, the studies investigating UCB for T2DM were far
more limited than T1DM. In the current analysis, 4
T1DM studies, while only a single T2DM study with
only 3 patients, were included [45]. This highlights the
crucial need for additional clinical studies to further elucidate the presence or absence of clinical efficacy of
UCB in T2DM. In fact, our findings regarding the lack
of clinical efficacy of UCB in DM come in agreement
with the results of the previous meta-analysis by ElBadawy and El-Badri, who also reported the uniformly
negative effect of UCB in children with T1DM, and failure to improve the glycemic status at 1 year posttransplantation [48]. Generally, autologous UCB infusion
in the included studies was reported to be safe and did
not cause undesirable side effects. However, the lack of
therapeutic efficacy warrants further investigations to
optimize the transplantation regimen. The authors explained the lack of efficacy of autologous UCB by the
probably insufficient number of cells with immunoregulatory/regenerative potential [43]. In fact, it is

Kassem and Kamal Stem Cell Research & Therapy

(2020) 11:484

important to point here that all these studies employed
autologous UCB nucleated cells, without any selection
or enrichment for any particular cell population. Interestingly, on the public clinical trial registry, there are
registered clinical trials currently recruiting patients to
assess safety and efficacy of UCB-derived regulatory T
cells (T-Regs) for T1DM; NCT02932826 and
NCT03011021 [49].
It is indeed important to point here that no serious adverse events were reported in any of the included studies. Generally, the studies for both WJ-MSCs and UCB
reported their safety, and the absence of any tumor formation throughout the whole follow-up period, based on
cancer-screening tests like tumor marker assessment
and/or imaging examination [35, 36, 38]. Occasionally,
only few transient adverse effects like mild fever, nausea,
vomiting, or headache [37], as well as abdominal pain or
puncture-site bleeding [39] which recovered spontaneously, were reported in nearly 5–20% of the patients
who received SC transplantation. As for the therapeutic
efficacy, various mechanisms have been proposed by
which WJ-MSCs could mediate their observed beneficial
effects in T1DM/T2DM [46]. Briefly, WJ-MSCs have the
ability for “homing” to sites of tissue injury and secrete
multiple bioactive mediators which are capable of stimulating recovery of injured cells, as well as various
immuno-modulatory functions [52, 53], and to a lesser
extent, the observed improvement in C-peptide levels
might also be attributed to their differentiation potential
into insulin-producing β cells [54–56]. On the other
hand, the putative therapeutic potential of UCB for DM
was originally based on their proposed immunomodulatory actions especially for T1DM being an autoimmune disease [57].
It is noteworthy here that for the six enrolled studies which employed WJ-MSCs, three of those studies
applied WJ-MSCs intravenously [35, 36, 38], a single
study transplanted the cells via the intra-pancreatic
artery in combination with BM-MNCs [39], and two
studies applied the cells via both intravenous and
intra-pancreatic routes [37, 40]. Generally, a dose of
1 × 106/kg was commonly reported for WJ-MSCs as
shown in Table 1. However, given the available data,
it is indeed important to point here that the best
route of delivery, number of cells, the frequency of
doses, and the time intervals between multiple doses
are still controversial issues. Future large scale welldesigned clinical studies will undoubtedly help to resolve these controversies to reach the optimum transplantation/dosage regimen.
It is indeed important to point here that both WJMSCs and UCB are readily available, non-invasive
sources of SC therapy, with banking potential. All of
these traits boost the feasibility/applicability of their
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therapeutic potential not only for DM, but for various
regenerative medicine applications. Nowadays, banking
of UCB is very well-established worldwide; however, for
UC-tissue/WJ-MSCs, this is not the case. Unfortunately,
neither the isolation/propagation, nor the cryopreservation protocols of GMP-compliant clinical grade WJMSCs are standardized worldwide. That is not going
along with the increasing number of reports highlighting
the therapeutic efficacy of WJ-MSCs in a wide-array of
diseases including DM [58].
Finally, although the current meta-analysis clearly
demonstrates the superior efficacy of WJ-MSCs over
UCB transplantation for improving both glycemic control and β cell function in patients with DM, several limitations must be kept in mind. First, the number of
included studies was quite limited and in most cases
with a relatively small number of patients. In addition,
the efficacy of WJ-MSCs in T1DM was evaluated in two
studies—one of these applied a co-intervention of WJMSCs with autologous BM-MNCs. Most importantly,
the effect of UCB in T2DM was evaluated in a single
study with a very limited number of enrolled patients,
resulting in a low statistical power. However, these limitations reflect the scarcity of reliable published data,
which employ these important readily available sources
of cell therapy for DM. This also sheds lights on the crucial need for additional well-designed randomized controlled trials with larger cohorts, in order to fill the
obvious gap between pre-clinical and clinical studies.
Further large-scale clinical studies are indeed warranted
to address several un-answered questions and enlighten
lots of dark spots, in order to maximize the therapeutic
benefit. These dark spots/un-answered questions include
the optimum transplantation regimen, route of administration, injected cell number, preference of autologous
or allogenic UC-SC therapy, and putative synergistic cointerventions. Additionally, further clinical studies are
required to investigate therapeutic efficacy of selected/
enriched UCB-derived cell populations with immunomodulatory/regenerative potential in DM.

Conclusions
To the best of our knowledge, this is the first study
which provides a focused consideration to evaluate the
clinical efficacy of umbilical cord-derived stem cells,
namely WJ-MSCs and UCB for DM. The results of our
study provide a clear evidence for the superior efficacy
of WJ-MSCs over UCB in DM. Basically, WJ-MSCs exhibited safety, as well as significant improvement for glycemic control, as well as β cell function, in DM. While
UCB, despite its demonstrated safety, it consistently
showed a lack of significant therapeutic effects. Moreover, WJ-MSCs resulted in decreased incidence of diabetic complications and ameliorated the need of
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exogenous insulin injection in some of those patients
who received such intervention. Nevertheless, further
large scale well-designed clinical trials are indeed warranted to confirm these encouraging observations, because they were based on limited number of studies with
relatively small cohorts. The results of the current study
also shed lights on the importance to consider cryopreservation/banking of WJ-MSCs together with the
well-established routine banking of UCB, especially for
those with family history of DM. Additionally, the
current study highlights the crucial need for additional
well-designed randomized controlled trials with larger
cohorts, in order to fill the obvious gap between preclinical and clinical studies. Undoubtedly, the future will
unravel much more findings concerned with the therapeutic mechanisms of action, as well as methods to
maximize the therapeutic benefits of WJ-MSCs.
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